Fundies. English
NLS PHARMACEUTICS LTD.
EDGAR231 filing records in this dataset, filed from 2020-02-28 to 2026-09-18. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- Not available
- Long-term debt including current maturities
- 113 thousand USD Source
Exact value
113130 USD
- Shares outstanding
- Not available
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-09-18.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 8 of 11 periods available· newest 2025-12-31
- Net income: 8 of 11 periods available· newest 2025-12-31
- Operating cash flow: 8 of 11 periods available· newest 2025-12-31
- Capital expenditure: 4 of 11 periods available· newest 2025-12-31
- Total assets: Multiple units; comparison withheld· newest 2025-12-31
- Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
- Current assets: Multiple units; comparison withheld· newest 2025-12-31
- Current liabilities: 7 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
- Long-term debt including current maturities: 1 of 11 periods available· newest 2020-12-31
- Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 1.1 millionPrior period
−USD 7.2 million
–
Current period
−USD 8.3 million
–
Exact inputs and evidence
-8300000 − -7197000 = -1103000 USD
-7197000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-8300000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 1.7 millionPrior period
−USD 1.07 million
–
Current period
−USD 2.77 million
–
Exact inputs and evidence
-2766000 − -1066000 = -1700000 USD
-1066000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-2766000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+33.3%Prior period
USD 6,000
–
Current period
USD 8,000
–
Exact inputs and evidence
8000 − 6000 = 2000 USD
6000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source8000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2018 2018-01-01 – 2018-12-31 | −USD 5.15 million Exact valueExact value: -5146766 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.73 million Exact valueExact value: -2732804 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2019 2019-01-01 – 2019-12-31 | −USD 5.45 million Exact valueExact value: -5447145 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 190,009 Exact valueExact value: -190009 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2020 2020-01-01 – 2020-12-31 | −USD 2.86 million Exact valueExact value: -2861435 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 729,386 Exact valueExact value: -729386 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2021 2021-01-01 – 2021-12-31 | −USD 11.95 million Exact valueExact value: -11946078 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 14.94 million Exact valueExact value: -14936044 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 39,560 Exact valueExact value: 39560 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 14.98 million Calculation and evidence-14936044 − 39560 USD Exact free cash flow: -14975604 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2022 2022-01-01 – 2022-12-31 | −USD 16.5 million Exact valueExact value: -16495680 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 13.88 million Exact valueExact value: -13879371 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2023-01-01 – 2023-12-31 | −USD 3.33 million Exact valueExact value: -3332000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 3.44 million Exact valueExact value: -3444000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 6,000 Exact valueExact value: 6000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 3.45 million Calculation and evidence-3444000 − 6000 USD Exact free cash flow: -3450000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2024-01-01 – 2024-12-31 | −USD 7.2 million Exact valueExact value: -7197000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.07 million Exact valueExact value: -1066000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 6,000 Exact valueExact value: 6000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.07 million Calculation and evidence-1066000 − 6000 USD Exact free cash flow: -1072000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | −USD 8.3 million Exact valueExact value: -8300000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.77 million Exact valueExact value: -2766000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 8,000 Exact valueExact value: 8000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.77 million Calculation and evidence-2766000 − 8000 USD Exact free cash flow: -2774000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
231 filings · 695 latest values · 695 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001783036, 1783036, NCEL, NLSP, edgar:1783036
Also known as NEWCELX LTD., NLS PHARMACEUTICS LTD., NLS Pharmaceutics Ltd., NLS Pharmaceutics Ltd. , NewcelX Ltd.